Auxogyn, Merck KGaA sales and marketing update

Auxogyn granted Merck's Merck Serono S.A. unit exclusive rights to commercialize Auxogyn's Early Embryo Viability Assessment (Eeva) test in Europe and Canada. Merck also has the option to extend the right to undisclosed countries and regions. The companies are not disclosing financial details. Auxogyn retains rights in the U.S. In 2012, Merck Serono partnered to develop Eeva with Auxogyn (see BioCentury, Oct. 29, 2012). ...